文献速递胸部肿瘤

小细胞肺癌免疫微环境:PD-L1表达分布与FOXP3阳性肿瘤浸润淋巴细胞的预后作用

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
PubMed 文献 · Eur J Cancer · 2018-08-01

该回顾性研究分析104例小细胞肺癌(SCLC)病例,采用免疫组化评估肿瘤细胞(TCs)和肿瘤浸润免疫细胞(TIICs)的PD-L1表达(22C3抗体,1%为cut-off),并以半定量评分分析CD8和FOXP3阳性TILs。结果显示PD-L1在TCs和TIICs的表达率分别为25%和40%,I-III期高于转移性患者;FOXP3阳性TILs在非转移患者中与改善预后相关(多因素HR 0.37,95%CI 0.17-0.81,p=0.013)。

要点

  • SCLC免疫微环境可能因分期而异,I-III期PD-L1表达高于转移性患者
  • FOXP3阳性TILs是非转移性SCLC的潜在预后标志物
  • PD-L1在TCs和TIICs的表达率分别为25%和40%

核心结论

  • SCLC的免疫微环境可能因分期不同而存在差异。
  • FOXP3阳性TILs是I-III期SCLC的潜在预后标志物,值得进一步研究。

研究设计与样本

  • 回顾性分析104例SCLC病例,包括66例I-III期患者(48例手术切除,18例根治性放化疗)和38例转移性病例。
  • 采用抗PD-L1 22C3抗体(DAKO)免疫组化评估肿瘤细胞和肿瘤浸润免疫细胞的PD-L1表达,以1%为cut-off。
  • 采用抗CD8和抗FOXP3抗体表征肿瘤浸润淋巴细胞,使用半定量评分并分类为阳性 vs 阴性/低。

主要发现

  • 在总体研究人群中,PD-L1在肿瘤细胞和肿瘤浸润免疫细胞中的表达率分别为25%和40%。
  • I-III期患者PD-L1阳性比例显著高于转移性患者:肿瘤细胞32% vs 13%(p=0.034),肿瘤浸润免疫细胞51.5% vs 21%(p=0.002)。
  • CD8阳性和FOXP3阳性TILs分别存在于59%和72%的样本中。
  • FOXP3阳性TILs在非转移患者中与改善预后相关,单因素分析生存HR为0.32(95%CI 0.16-0.7,p=0.006)。
  • 多因素分析中FOXP3阳性TILs的生存HR为0.37(95%CI 0.17-0.81,p=0.013)。

关键数值与推荐

  • PD-L1免疫组化使用抗PD-L1 22C3抗体(DAKO),以1%作为cut-off点。
  • TILs半定量评分分类为阳性 vs 阴性/低。

临床怎么用

  • 对于I-III期SCLC患者,FOXP3阳性TILs可能作为预后评估的潜在标志物。
  • SCLC免疫微环境特征因分期而异,提示免疫治疗策略可能需要考虑分期因素。

局限性

  • 本研究为回顾性分析,样本量有限(104例)。
  • FOXP3阳性TILs的预后价值需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The prognosis of small-cell lung cancer (SCLC) is dismal and new effective therapies are needed. Immunotherapy looks promising, but no molecular predictive markers are currently available, and data on immune microenvironment are very limited. METHODS: We retrospectively analysed 104 SCLC cases. Immunohistochemistry evaluation of PD-L1 was performed both on tumour cells (TCs) and on tumour-infiltrating immune cells (TIICs) by using anti-PD-L1 22C3 antibody (DAKO) and categorised by using 1% as cut-off point. Tumour-infiltrating lymphocytes (TILs) were characterised by using anti-CD8 and anti-FOXP3 antibodies. Semi-quantitative score was used and categorised as positive versus negative/low. The relation of molecular markers with prognosis and with clinical variables was evaluated. RESULTS: The analysis included 66 stage I-III patients (48 surgically resected, 18 treated with radical-intent chemoradiotherapy) and 38 metastatic cases. In the overall study population, PD-L1 was expressed on TCs and TIICs in 25% and 40% of cases, respectively. The proportion of PD-L1-positive cases was significantly higher in stage I-III versus metastatic patients (32% versus 13%, p: 0.034 for TCs; 51.5% versus 21% for TIICs, p: 0.002). CD8- and FOXP3-positive TILs were present in 59% and 72% of samples, respectively. The presence of FOXP3-TILs was associated with improved prognosis among non-metastatic patients, with a hazard ratio for survival of 0.32 (95% confidence interval [CI]: 0.16-0.7, p: 0.006) for univariate analysis, and 0.37 (95% CI: 0.17-0.81, p: 0.013) for multivariate analysis. CONCLUSIONS: Immune contexture of SCLC may differ according to stage. The presence of FOXP3-positive TILs is a potential prognostic marker for stage I-III SCLCs and warrants further investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bonanno L, Pavan A, Dieci MV, et al. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Eur J Cancer. 2018. PMID: 30077124. doi:10.1016/j.ejca.2018.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。